Xencor (XNCR) Change in Receivables (2016 - 2026)
Xencor (XNCR) posted quarterly Change in Receivables of -$5.8 million for Q1 2026, up 75.22% year-over-year from -$3.3 million in Q1 2025, and up 75.22% quarter-over-quarter from -$23.4 million in Q1 2025.
Powered by 
Analysis
Xencor (XNCR) Change in Receivables (2016 - 2026) Analysis & Trends
Xencor (XNCR) has reported Change in Receivables for 9 consecutive years, with -$5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 75.22% year-over-year to -$5.8 million; the TTM figure through Mar 2026 stood at -$77.5 million (down 72.63% YoY), while the FY2025 annual figure was -$28.7 million, down 187.94% from the prior year.
- Change in Receivables advanced to -$5.8 million in Q1 2026 per XNCR's latest filing, from -$23.4 million in the prior quarter.
- Across five years, Change in Receivables topped out at $26.8 million in Q1 2022 and bottomed at -$38.9 million in Q2 2022.
- Historically, Change in Receivables has averaged -$10.1 million across 3 years, with a median of -$9.4 million in 2022.
- On a YoY basis, Change in Receivables climbed as much as 2378.74% in 2022 and fell as far as 301.24% in 2022.
- Xencor's Change in Receivables stood at -$9.4 million in 2022, then plunged by 148.78% to -$23.4 million in 2025, then jumped by 75.22% to -$5.8 million in 2026.
- Business Quant data shows XNCR's Change in Receivables at -$5.8 million in Q1 2026, -$23.4 million in Q1 2025, and -$9.4 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 28.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.44 Mn |
| Mar 31, 2026 | -5.80 Mn |
| Jun 30, 2025 | 8.77 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Sep 30, 2022 | -9.41 Mn |
| Jun 30, 2022 | -38.92 Mn |
| Mar 31, 2022 | 26.82 Mn |
| Dec 31, 2021 | 58.34 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Jun 30, 2021 | -9.70 Mn |
| Mar 31, 2021 | 1.08 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Sep 30, 2020 | 609,000.00 |
| Jun 30, 2020 | 2.10 Mn |
| Mar 31, 2020 | -14.75 Mn |
| Dec 31, 2019 | 17.22 Mn |
| Sep 30, 2019 | -5.78 Mn |
| Jun 30, 2019 | -127.61 Mn |
| Mar 31, 2019 | 127.49 Mn |
| Dec 31, 2018 | 7.73 Mn |